Mandate

Vinge advises Vinci Concessions SAS and its subsidiary SunMind SAS in connection with its acquisition of Helios Nordic Energy AB from Magnora ASA, management and early investors

Helios Nordic Energy specialises in developing solar farms and batteries to store energy until they become Ready to Build in the Nordics and Baltics.

The acquisition will enable SunMind to further enrich its expertise in renewable solar energy and other sources of renewable energy.

The current owners of Helios will receive an upfront payment of approximately EUR 73 million as well as a substantial earnout component tied to Helios's portfolio of unsold projects stretching over five years from closing.

The acquisition is subject to customary regulatory approvals.

Vinge's team primarily consisted of Peter Sundgren, Martin E Svanberg, Hanna Jansson and Fredrik Löwenclou (M&A), Amelia Rihs (Employment), Johan Cederblad and Lina Österberg (Environmental law), Kristoffer Larsson and Jasdeep Singh (Real Estate), Jolene Reimersson och Mario Saad (Commercial Agreements), Mia Falk (Compliance), David Olander and Lovisa Lewin (Regulatory),  Cecilia Loctander and  Caroline Löv (Transaction Support Coordinators).

Related

Vinge has advised Oncopeptides in connection with its rights issue

Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025

Vinge advises Main Capital and Unik in connection with the acquisition of LEB System Aktiebolag

Vinge has advised Unik International ApS (“Unik”), a Danish Housing and Property Management software provider, in connection with the acquisition of LEB System Aktiebolag. The synergistic acquisition is expected to complement and expand Unik’s offering and has a strong strategic fit with Unik and is in line with the company’s internationalization strategy in the Nordic Property Management software market.
August 28, 2025

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.
August 28, 2025